Drospirenone API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals

 

Drospirenone API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals

1. Introduction

Drospirenone is a synthetic steroidal progestin developed for use in hormonal pharmaceutical formulations. It is structurally related to spironolactone and has progestogenic, antimineralocorticoid and antiandrogenic properties.

It is used in different oral pharmaceutical products, including progestin-only contraceptive tablets and combination hormonal contraceptives containing an estrogen. It is also combined with estetrol in certain approved contraceptive formulations.

Drospirenone is an important API for pharmaceutical manufacturers working in women's healthcare, hormonal medicines and oral contraceptive development. Its chemical identity, stereochemical purity, impurity profile, solid-state properties and analytical quality require careful evaluation during API procurement and formulation development.

2. What Is Drospirenone API?

Drospirenone API is a synthetic steroidal active pharmaceutical ingredient belonging to the progestin class.

Unlike some conventional synthetic progestins, drospirenone has additional antimineralocorticoid and antiandrogenic properties. These characteristics are related to its structural similarity to spironolactone.

Drospirenone is used in:

  • Progestin-only oral contraceptive formulations.

  • Combined oral contraceptives containing ethinyl estradiol.

  • Combined oral contraceptives containing estetrol.

  • Selected hormonal formulations developed for specific women's healthcare applications.

The API is generally used as drospirenone itself rather than as a conventional acid-addition salt. Pharmaceutical manufacturers should verify the exact material identity and solid-state form against the supplier's technical documentation.

3. Chemical Information of Drospirenone API

PropertyDetails
Generic NameDrospirenone
CAS Number67392-87-4
Molecular FormulaC24H30O3
Molecular WeightApproximately 366.50 g/mol
Chemical ClassSynthetic Steroidal Progestin
Pharmacological ClassProgestogen
Structural TypeSteroid Lactone
Physical DescriptionWhite to almost white or slightly yellow crystalline powder, as described in product labelling
Common Pharmaceutical FormOral tablets
Molecular NatureNeutral steroidal compound

Drospirenone has a molecular formula of C24H30O3 and a molecular weight of approximately 366.50 g/mol. It is a neutral molecule and should not be confused with a mesylate, hydrochloride or other salt form.

Its molecular structure contains multiple stereogenic centres. Maintaining the correct stereochemical configuration is essential for confirming the identity and quality of the API.

4. Chemical Structure and Important Functional Groups

Drospirenone is a synthetic steroidal compound with a complex polycyclic structure.

Its molecular structure contains several important features:

4.1 Steroidal Framework

The steroidal framework provides the structural foundation for its interaction with progesterone-related biological pathways.

4.2 Spirocyclic Lactone Structure

Drospirenone contains a distinctive spirocyclic lactone arrangement. This structural feature contributes to its chemical identity and distinguishes it from several other synthetic progestins.

4.3 Ketone Groups

The molecule contains carbonyl groups that contribute to its chemical characteristics and molecular structure.

4.4 Stereochemical Centres

Drospirenone has multiple defined stereogenic centres. Stereochemical control is therefore important during manufacturing, purification and analytical testing.

4.5 Hydrocarbon-Rich Structure

Its steroidal framework contains a substantial hydrocarbon component, contributing to its lipophilic character and limited water solubility.

5. Mechanism of Action of Drospirenone

Drospirenone acts primarily through progestogenic activity. Its pharmacological properties also include antimineralocorticoid and antiandrogenic effects.

5.1 Progestogenic Activity

Drospirenone interacts with progesterone receptors and produces effects associated with progestins.

In contraceptive formulations, the primary mechanism involves suppression of ovulation. Depending on the formulation, it also contributes to changes in cervical mucus and the endometrial environment.

5.2 Antimineralocorticoid Activity

Drospirenone is structurally related to spironolactone and has antimineralocorticoid activity.

It can oppose certain effects of aldosterone, a hormone involved in regulating sodium and potassium balance. This activity is relevant to its pharmacological profile and is also the reason potassium-related precautions are important.

5.3 Antiandrogenic Activity

Drospirenone has antiandrogenic properties, meaning that it can oppose certain androgen-related biological effects.

This property is relevant to the pharmacological profile of some combination hormonal products containing drospirenone.

Important distinction: Drospirenone's individual pharmacological activities should not be confused with the complete mechanism of a finished combination product. For example, the contraceptive action of a drospirenone-only tablet and that of a drospirenone-plus-estrogen tablet involves the complete formulation and its approved product information.

6. Pharmaceutical Applications of Drospirenone API

Drospirenone is used in several types of oral hormonal formulations.

6.1 Progestin-Only Contraceptive Tablets

Drospirenone is used as the sole hormonal active ingredient in certain oral contraceptive products.

An example is SLYND, a US-approved progestin-only product containing 4 mg drospirenone in each active tablet.

This formulation demonstrates the use of drospirenone without an estrogen component.

6.2 Combined Oral Contraceptives

Drospirenone is combined with ethinyl estradiol in certain oral contraceptive products.

An example is the combination of:

  • Drospirenone: 3 mg

  • Ethinyl estradiol: 0.02 mg

Such combinations are used for oral contraception. Depending on the specific approved product and market, certain formulations also have indications relating to premenstrual dysphoric disorder (PMDD) or moderate acne.

6.3 Drospirenone and Estetrol Formulations

Drospirenone is also used in combination with estetrol in certain approved contraceptive products.

For example, the European Medicines Agency product information for Drovelis describes active tablets containing 3 mg drospirenone and 14.2 mg estetrol, expressed as estetrol monohydrate equivalent.

6.4 Hormonal Pharmaceutical Development

Drospirenone is relevant to pharmaceutical development involving:

  • Women's healthcare products.

  • Oral hormonal formulations.

  • Progestin-only contraceptives.

  • Combined estrogen-progestin formulations.

  • Research and development of steroidal pharmaceutical products.

The intended indication and formulation must always be checked against the relevant country's approved product information.

7. Common Drospirenone Pharmaceutical Formulations

Drospirenone is primarily associated with oral tablet formulations.

Formulation TypeExample CompositionApplication
Progestin-only tabletDrospirenone 4 mgOral contraception
Combined oral contraceptiveDrospirenone 3 mg + Ethinyl estradiol 0.02 mgOral contraception and certain additional approved uses
Combined oral contraceptiveDrospirenone 3 mg + Estetrol 14.2 mgOral contraception

These are examples of marketed product compositions, not universal formulation requirements.

7.1 Immediate-Release Tablets

Drospirenone is used in conventional oral tablet products. Formulation development must consider the API's solubility, particle properties, dissolution behaviour and compatibility with excipients.

7.2 Combination Tablets

In combination products, drospirenone may be formulated with an estrogen such as ethinyl estradiol or estetrol.

The formulation developer must evaluate the compatibility and stability of each active ingredient and ensure that the finished product meets its approved quality requirements.

7.3 Active and Placebo Tablet Packs

Some marketed contraceptive products use blister packs containing active tablets and inactive placebo tablets. Packaging design and tablet identification must support the approved dosing sequence.

8. Manufacturing Considerations for Drospirenone API

Drospirenone is a complex steroidal molecule. Its manufacturing requires control of chemical transformations, stereochemistry, purification and final material quality.

Important manufacturing considerations include:

8.1 Starting Material Quality

The identity, purity and suitability of steroidal starting materials should be evaluated. Starting-material impurities can influence the quality of intermediates and the final API.

8.2 Reaction Control

Chemical reactions should be controlled to achieve the intended transformations while limiting unwanted side reactions.

Appropriate process monitoring helps maintain consistency between manufacturing batches.

8.3 Stereochemical Integrity

Drospirenone has multiple defined stereogenic centres. Maintaining the intended stereochemical configuration is essential.

Stereochemical impurities should be assessed using appropriate analytical techniques where required by the material specification.

8.4 Impurity Control

Process-related impurities, residual starting materials, intermediates and degradation products should be controlled through validated purification and analytical procedures.

8.5 Crystallisation and Solid-State Characteristics

Crystallisation conditions may influence particle size, crystal habit and solid-state characteristics.

These properties can affect powder handling, blending, compression and dissolution during tablet manufacturing.

8.6 Drying and Packaging

Drying and packaging operations should be designed to maintain material quality and protect the API during storage and transportation.

The final packaging system should be supported by suitable stability and compatibility data.

9. Quality Control and Testing of Drospirenone API

Quality control is essential to establish the identity, purity and suitability of drospirenone API for pharmaceutical manufacturing.

The exact tests and acceptance criteria should be based on the applicable current pharmacopoeial monograph, approved specification and regulatory requirements.

Important quality-control parameters include:

Quality ParameterPurpose
DescriptionEvaluates physical appearance
IdentificationConfirms chemical identity
AssayDetermines drospirenone content
Related SubstancesControls process-related and degradation impurities
Stereochemical PurityEvaluates the required stereochemical identity
Water ContentAssesses moisture content
Residual SolventsControls solvents remaining from manufacturing
Elemental ImpuritiesEvaluates relevant inorganic contaminants
Particle Size DistributionSupports formulation and processing
Solid-State CharacterisationEvaluates crystalline form
Microbiological QualityAssesses applicable microbial requirements

9.1 HPLC Analysis

High-performance liquid chromatography (HPLC) is an important technique for pharmaceutical assay and related-substance analysis.

A suitable validated method can help determine drospirenone content and evaluate relevant impurities.

9.2 FTIR Analysis

Fourier-transform infrared spectroscopy (FTIR) can support chemical identification by evaluating characteristic absorption bands associated with the molecule's functional groups.

9.3 LC-MS Analysis

Liquid chromatography-mass spectrometry (LC-MS) may be used for the characterisation of impurities and degradation products.

It can provide additional information about molecular mass and fragmentation patterns.

9.4 Stereochemical Analysis

Because drospirenone contains multiple stereogenic centres, appropriate stereochemical testing may be necessary to confirm that the material meets the intended identity and purity requirements.

9.5 Water and Residual Solvent Testing

Water content and residual solvents should be evaluated using suitable validated methods according to the applicable specification.

10. Stability and Degradation of Drospirenone

Stability assessment is an important part of drospirenone API development and finished-product manufacturing.

The stability profile should be established through appropriate studies using validated analytical procedures.

Factors that may influence material or finished-product stability include:

  • Temperature.

  • Moisture and humidity.

  • Light exposure.

  • Oxidative conditions.

  • Packaging compatibility.

  • Excipient interactions.

  • Physical changes during storage.

Stability-indicating analytical methods should be capable of separating the active ingredient from relevant degradation products.

Pharmaceutical manufacturers should establish appropriate storage conditions and retest periods using supporting stability data rather than relying on generic storage assumptions.

11. Safety and Regulatory Considerations

Drospirenone is used in prescription hormonal products in several markets. Its commercialisation and formulation require compliance with the applicable pharmaceutical and regulatory requirements.

Important clinical safety considerations include:

11.1 Hyperkalemia

Drospirenone has antimineralocorticoid activity and may increase serum potassium concentrations.

The risk is particularly relevant in people with certain medical conditions or those taking other medicines that can increase potassium levels.

Product labels describe potassium monitoring for selected patients and list relevant contraindications.

11.2 Venous Thromboembolism

Combined hormonal contraceptives containing drospirenone and an estrogen may be associated with venous thromboembolism risk.

The risk assessment depends on the complete formulation and individual clinical factors. It should not be assumed that the risk profile of a drospirenone-only product is identical to that of a combined hormonal contraceptive.

11.3 Renal and Hepatic Considerations

Certain drospirenone-containing products have contraindications relating to renal or hepatic impairment. The exact restrictions depend on the product's approved label.

11.4 Drug Interactions

Medicines that induce certain metabolic enzymes, including CYP3A4, may reduce drospirenone exposure and potentially affect contraceptive effectiveness.

Other medicines may increase potassium-related risks when used with drospirenone.

11.5 Regulatory Documentation

Pharmaceutical manufacturers should assess:

  • Applicable GMP requirements.

  • API identity and specifications.

  • Impurity and residual-solvent controls.

  • Analytical method validation.

  • Stability documentation.

  • Packaging and labelling requirements.

  • Regulatory authorisation for the intended market.

Clinical safety statements should be based on the current approved label for the exact finished product.

12. Drospirenone Compared with Other Progestins

Drospirenone belongs to the synthetic progestin group. However, it has a distinct pharmacological profile compared with several other commonly used progestins.

ParameterDrospirenoneLevonorgestrelDesogestrelNorethindrone
Drug ClassSynthetic ProgestinSynthetic ProgestinSynthetic ProgestinSynthetic Progestin
Structural FamilySteroidal19-Nortestosterone derivative19-Nortestosterone derivative19-Nortestosterone derivative
Progestogenic ActivityYesYesYesYes
Antimineralocorticoid ActivityYesNo comparable activityNo comparable activityNo comparable activity
Antiandrogenic ActivityYesAndrogenic activity may be presentLow androgenic activityAndrogenic activity may be present
Formulation UsesProgestin-only and combined hormonal productsProgestin-only and combined productsProgestin-only and combined productsProgestin-only and combined products

These compounds differ in receptor activity, pharmacokinetics, formulation characteristics and clinical safety profiles. They should not be treated as directly interchangeable APIs.

13. Factors to Consider When Procuring Drospirenone API

Pharmaceutical manufacturers and procurement teams should evaluate the following factors when selecting a drospirenone API source.

13.1 Chemical Identity

Confirm the product name, CAS number, molecular formula and molecular weight.

For drospirenone, verify that the offered material is the intended neutral steroidal compound rather than an incorrectly identified derivative or related substance.

13.2 Certificate of Analysis

Review the batch-specific Certificate of Analysis (CoA), including identification, assay and related-substance results.

13.3 Stereochemical Purity

Evaluate whether the supplier's analytical documentation adequately supports the required stereochemical identity and purity.

13.4 Impurity Profile

Review process-related impurities, degradation products and other relevant impurities against the agreed specification.

13.5 Analytical Documentation

Confirm the availability of appropriate analytical procedures and supporting validation or verification information.

13.6 Stability Data

Review stability studies, packaging information, storage conditions and the proposed retest period.

13.7 Regulatory Documentation

Assess the availability and suitability of required technical and regulatory documentation for the intended market.

13.8 Supplier Qualification

Evaluate the supplier's quality system, manufacturing documentation, traceability and ability to meet agreed quality requirements.

14. Why Quality Matters in Drospirenone API Selection

Drospirenone is used in low-dose hormonal formulations, making accurate assay, impurity control and formulation consistency especially important.

Important quality attributes include:

  • Correct molecular identity.

  • Correct stereochemical configuration.

  • Consistent assay results.

  • Controlled related substances.

  • Suitable particle characteristics.

  • Appropriate solid-state properties.

  • Reliable stability information.

  • Complete batch documentation.

A systematic API qualification process supports consistent formulation development and helps pharmaceutical manufacturers manage quality risks.

15. Drospirenone API Enquiries – Swapnroop Drugs & Pharmaceuticals

Swapnroop Drugs & Pharmaceuticals (SDP) works in the pharmaceutical raw material and API business.

Pharmaceutical manufacturers, formulation developers, distributors and procurement professionals can contact the company for relevant business enquiries concerning drospirenone and other pharmaceutical raw materials.

Before proceeding with procurement, buyers should confirm the exact material identity, required grade, batch-specific specification, technical documentation and regulatory suitability.

Enquiry details to confirm:

  • Product: Drospirenone API

  • CAS Number: 67392-87-4

  • Required quantity

  • Intended pharmaceutical application

  • Required quality specification

  • Analytical and regulatory documentation

  • Destination market

Product availability, specifications and commercial terms should be confirmed directly with the company.

16. Frequently Asked Questions About Drospirenone API

Q1. What is Drospirenone API?

Drospirenone API is a synthetic steroidal progestin used in the development of oral hormonal pharmaceutical formulations, including progestin-only and combined contraceptive products.

Q2. What is the CAS number of Drospirenone?

The CAS number of drospirenone is 67392-87-4.

Q3. What is the molecular formula of Drospirenone?

The molecular formula of drospirenone is C24H30O3.

Q4. What is the molecular weight of Drospirenone?

Drospirenone has a molecular weight of approximately 366.50 g/mol.

Q5. Is Drospirenone a steroid?

Yes. Drospirenone is a synthetic steroidal progestin with a distinctive spirocyclic lactone structure.

Q6. What is the mechanism of action of Drospirenone?

Drospirenone has progestogenic activity and is used in contraceptive formulations that suppress ovulation. It also has antimineralocorticoid and antiandrogenic properties.

Q7. What is Drospirenone used for in pharmaceutical formulations?

It is used in progestin-only contraceptive tablets and combination hormonal products containing estrogen components such as ethinyl estradiol or estetrol.

Q8. Is Drospirenone available as a salt?

Drospirenone is generally used as a neutral molecular compound rather than a conventional acid-addition salt. The exact material identity should be confirmed from its specification.

Q9. Which analytical methods are used for Drospirenone API testing?

HPLC is commonly relevant for assay and related-substance analysis. FTIR can support identification, while LC-MS and suitable stereochemical methods may support impurity characterisation and identity assessment.

Q10. Why is stereochemical purity important for Drospirenone?

Drospirenone contains multiple stereogenic centres. The correct stereochemical configuration is essential to establish the intended molecular identity and pharmaceutical quality.

Q11. What are the main quality parameters for Drospirenone API?

Important parameters include identification, assay, related substances, stereochemical purity, water content, residual solvents, elemental impurities and solid-state characteristics, as applicable to the approved specification.

Q12. What should buyers verify before procuring Drospirenone API in India?

Buyers should confirm CAS number, chemical identity, batch-specific CoA, assay, impurity profile, stereochemical quality, stability data, regulatory documentation and supplier qualification.

17. Conclusion

Drospirenone is an important synthetic steroidal progestin used in modern hormonal pharmaceutical formulations. Its progestogenic, antimineralocorticoid and antiandrogenic properties distinguish it from several other synthetic progestins.

For pharmaceutical manufacturers, selecting drospirenone API requires careful evaluation of chemical identity, stereochemical purity, assay, related substances, solid-state characteristics, stability and regulatory documentation.

Swapnroop Drugs & Pharmaceuticals welcomes relevant pharmaceutical business enquiries concerning drospirenone and other pharmaceutical raw materials. Buyers should confirm current availability, technical specifications and documentation before proceeding with procurement.

Comments

Popular posts from this blog

🌿 Probiotics IR Pellets – Fast-Acting Gut Health Solution by Swapnroop Drugs & Pharmaceuticals 🌿

🌱 Probiotics EC Pellets – Stabilized Gut Health Powerhouses by Swapnroop Drugs & Pharmaceuticals

Azithromycin Taste-Masked Powder: A Pediatric-Friendly Innovation by Swapnroop Drugs & Pharmaceuticals